We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App





BioMérieux SARS-CoV-2 Serology Tests Granted FDA Emergency Use Authorization

By LabMedica International staff writers
Posted on 11 Aug 2020
BioMérieux’s (Marcy-l'Étoile, France) has been granted Emergency Use Authorizations (EUAs) by the US Food and Drug Administration (FDA) for two SARS-CoV-2 serology tests.

The FDA has granted EUA to BioMérieux’s VIDAS SARS-COV-2 IgM and VIDAS SARS-COV-2 IgG automated qualitative assays which rapidly detect antibodies to help identify individuals with previous exposure to SARS-CoV-2. More...
With the same protocols to differentiate IgM and IgG results, the VIDAS SARS-COV-2 IgM detects IgM specific for SARS-CoV-2 while the VIDAS SARS-COV-2 IgG detects IgG specific for SARS-CoV-2.

Both the assays use a two-step sandwich enzyme immunoassay method with final fluorescence detection (ELFA). Available on-demand 24/7 on all VIDAS platforms, they offer flexibility and reliability for results in less than 30 minutes. All the assay steps are performed automatically by the instrument which is intuitive and easy to use with limited maintenance, calibration and controls. Both the assays deliver a performance with high specificity and sensitivity from day eight and generate results that help provide additional pandemic analysis data. According to the FDA, both the tests can be used by any lab CLIA-certified to perform moderate- or high-complexity testing.

Related Links:

BioMérieux


Gold Member
Multiplex Genetic Analyzer
MassARRAY Dx Analyzer (Europe only)
Collection and Transport System
PurSafe Plus®
New
Gold Member
Automatic Chemiluminescence Immunoassay Analyzer
Shine i2000
Gold Member
Automatic Hematology Analyzer
DH-800 Series
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: The CloneSeq-SV approach can allow researchers to study how cells within high-grade serous ovarian cancer change over time (Photo courtesy of MSK)

Blood Test Tracks Treatment Resistance in High-Grade Serous Ovarian Cancer

High-grade serous ovarian cancer (HGSOC) is often diagnosed at an advanced stage because it spreads microscopically throughout the abdomen, and although initial surgery and chemotherapy can work, most... Read more

Pathology

view channel
Image: The new system allows surgeons to identify genotyping of brain tumors and determine optimal resection margins during surgery (Photo courtesy of Nagoya University)

New Technique Detects Genetic Mutations in Brain Tumors During Surgery within 25 Minutes

Determining the genetic profile of brain tumors during surgery is crucial for improving patient outcomes, but conventional analysis methods can take up to two days, delaying critical decisions.... Read more

Industry

view channel
Image: The collaboration aims to improve access to Hb variant testing with the Gazelle POC diagnostic platform (Photo courtesy of Hemex Health)

Terumo BCT and Hemex Health Collaborate to Improve Access to Testing for Hemoglobin Disorders

Millions of people worldwide living with sickle cell disease and other hemoglobin disorders experience delayed diagnosis and limited access to effective care, particularly in regions where testing is scarce.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.